

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Mamopoulos 1



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Apostolos	2. Surname (Last Name) Mamopoulos		3. Date 21-March-2016
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Na Guillermina Girardi	ame
5. Manuscript Title Effects of pravastatin in the manageme	ent of obstetric antiphosph	olipid syndrome refractor	y to antithrombotic therapy
6. Manuscript Identifying Number (if you k 86957-JCI-CMED	now it)		
Section 2. The Work Under C	Consideration for Public	ration	
Did you or your institution at any time rece any aspect of the submitted work (includin statistical analysis, etc.)?	eive payment or services from g but not limited to grants, da	a third party (government, co	
Are there any relevant conflicts of inte	rest? Yes No		ADD
Section 3. Relevant financial	l activities outside the s	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as desc clicking the "Add +" box. You should re Are there any relevant conflicts of inter	ribed in the instructions. Use port relationships that we	se one line for each entity;	add as many lines as you need by
			ADD
Section 4. Intellectual Prope	rty Patents & Copyri	ghts	
Do you have any patents, whether plan	nned, pending or issued, br	oadly relevant to the work	√? Yes ✓ No

Mamopoulos 2



Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. Section 6. Disclosure Statement Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Generate Disclosure Statement

Dr. Mamopoulos has nothing to disclose.



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Christos	2. Surname (Last Name) Vosnakis	3. Date 21-March-2016
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Guillermina Girardi
5. Manuscript Title Effects of pravastatin in the manageme	ent of obstetric antiphosph	nolipid syndrome refractory to antithrombotic therapy
6. Manuscript Identifying Number (if you k 86957-JCI-CMED	now it)	
Section 2. The Week Under C		
Did you or your institution at any time rece		cation a third party (government, commercial, private foundation, etc.) for at a monitoring board, study design, manuscript preparation,
statistical analysis, etc.)? Are there any relevant conflicts of inter	rest? Yes V No	ADD
Section 3.		
Place a check in the appropriate boxes of compensation) with entities as descr	ribed in the instructions. U port relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. ADD
Section 4. Intellectual Prope	rty Patents & Copyri	ghts
Do you have any patents, whether plan	nned, pending or issued, b	roadly relevant to the work? Yes V No

Vosnakis 2



Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Generate Disclosure Statement

Dr. Vosnakis has nothing to disclose.



Section 1.	Identifying Inforn	nation	
1. Given Name (Fi David	rst Name)	2. Surname (Last Na Rousso	me) 3. Date 22-March-2016
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Guillermina Girardi
5. Manuscript Title Effects of pravas		ent of obstetric antiph	nospholipid syndrome refractory to antithrombotic therapy
6. Manuscript Idea 86957-JCI-CMED	ntifying Number (if you kı)	now it)	
Section 2.			
	The Work Under C		ublication from a third party (government, commercial, private foundation, etc.) for
statistical analysis,			nts, data monitoring board, study design, manuscript preparation,
Are there any rei	evant conflicts of inter	est? Yes ✓	No ADD
Section 3.	Relevant financial	activities outside	the submitted work.
of compensation	n) with entities as descr	ibed in the instructio	e whether you have financial relationships (regardless of amount ns. Use one line for each entity; add as many lines as you need by
5	evant conflicts of inter		nt were present during the 36 months prior to publication . No
			ADD
Section 4.	Intellectual Prope	rty Patents & Co	pyrights
Do you have any	patents, whether plan	ned, pending or issu	ed, broadly relevant to the work? Yes Vo

Rousso 2



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Dis	closure Statement
Dr. Rousso has n	othing to disclose.



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Eleftheria	2. Surname (Last Name) Lefkou	3. Date 21-March-2016
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Guillermina Girardi
5. Manuscript Title Effects of pravastatin in the manageme	ent of obstetric antiphosph	nolipid syndrome refractory to antithrombotic therapy
6. Manuscript Identifying Number (if you k 86957-JCI-CMED	now it)	
Section 2.	onsideration for Publi	
Did you or your institution at any time rece	eive payment or services from	n a third party (government, commercial, private foundation, etc.) for at a monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of inter	rest? Yes No	ADD
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as desc	ribed in the instructions. Use port relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .
		ADD
Section 4. Intellectual Prope	rty Patents & Copyri	ghts
Do you have any patents, whether plan	nned, pending or issued, br	roadly relevant to the work? Yes Yo

Lefkou 2



Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. Section 6. Disclosure Statement Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Generate Disclosure Statement

Dr. Lefkou has nothing to disclose.



Section 1. Identifying Inform		
Identifying Inform	nation	
Given Name (First Name) Guillermina	2. Surname (Last Name) Girardi	3. Date 20-March-2016
4. Are you the corresponding author?	√ Yes No	
5. Manuscript Title Effects of pravastatin in the manageme	ent of obstetric antiphospholipid synd	rome refractory to antithrombotic therapy
6. Manuscript Identifying Number (if you k 86957-JCI-CMED	now it)	
Section 2. The Work Under C	Consideration for Publication	
	g but not limited to grants, data monitorin	(government, commercial, private foundation, etc.) for g board, study design, manuscript preparation,
Are there any relevant conflicts of inter	rest? Yes 🗸 No	ADD
Section 3. Belowert financial		
Relevant financial	activities outside the submitted	work.
of compensation) with entities as descr	ribed in the instructions. Use one line f	ave financial relationships (regardless of amount for each entity; add as many lines as you need by furing the 36 months prior to publication.
Are there any relevant conflicts of inter	rest? Yes 🗸 No	
		ADD
Section 4. Intellectual Prope	rty Patents & Copyrights	
Do you have any patents, whether plar	nned, pending or issued, broadly releva	ant to the work? Yes V No

Girardi 2



6 - N - E	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
On occasion, jou	inuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements mals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	we disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Dis	closure Statement
Dr. Girardi has no	othing to disclose.



Section 1.	ldentifying Inforn	nation	
1. Given Name (Fi Themistoklis	rst Name)	2. Surname (Last Name) Dagklis	3. Date 21-March-2016
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Guillermina Girardi
5. Manuscript Title Effects of pravas		ent of obstetric antiphosp	pholipid syndrome refractory to antithrombotic therapy
6. Manuscript Ide 86957-JCI-CMED	ntifying Number (if you k)	now it)	
Section 2.	The Week Heden C	onsideration for Pub	Backley
any aspect of the s statistical analysis,	stitution at any time rece submitted work (including	eive payment or services fro g but not limited to grants,	om a third party (government, commercial, private foundation, etc.) for data monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the	
			e submitted work.
of compensation clicking the "Add	n) with entities as descr	ribed in the instructions. port relationships that w	whether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by were present during the 36 months prior to publication .
of compensation clicking the "Add	n) with entities as descr I+" box. You should re evant conflicts of inter	ribed in the instructions. port relationships that w	whether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by were present during the 36 months prior to publication . ADD

Dagklis 2



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of incing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Generate Dis	closure Statement
Dr. Dagklis has n	othing to disclose.

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
C		exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment
1		and control selection. Give the rationale for the choice of cases and controls
		(b) For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
, without	,	modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) If applicable, explain how matching of cases and controls was addressed
		(e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
F	_	eligible, examined for eligibility, confirmed eligible, included in the study,
		completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and
1		information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
	-	their precision (eg, 95% confidence interval). Make clear which confounders were
		adjusted for and why they were included
		(b) Report category boundaries when continuous variables were categorized
		(b) Report category boundaries when continuous variables were categorized(c) If relevant, consider translating estimates of relative risk into absolute risk for a

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.
		Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
		of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other informati	ion	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,
		for the original study on which the present article is based

^{*}Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.